Loading...
•
Dec 31, 2022
NextCure Q4 2022 Earnings Report
NextCure reported full year 2022 financial results and provided a business update.
Key Takeaways
NextCure reported its full year 2022 financial results, highlighting a cash position of approximately $160 million expected to fund operations into mid-2025. The company anticipates data updates on all three clinical programs in 2023.
Ended 2022 with approximately $160 million in cash, expected to fund operations into mid-2025.
NC525 (LAIR-1 mAb) dosed first patient in a Phase 1 trial in acute myeloid leukemia (AML).
Phase 1b update for NC762 is expected in the fourth quarter of 2023.
Initial Phase 1a data for NC525 is expected in the fourth quarter of 2023.
Forward Guidance
NextCure expects its existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditures into mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...